QBiotics Group is a life sciences company that discovers, develops, and commercializes pharmaceuticals for human and veterinary markets. It focuses on cancer, specifically solid tumours, and chronic wound management areas. The company develops tigilanol tiglate (EBC-46), an oncology product for the treatment of solid tumour cancers, and EBC-1013, a wound healing product.